Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.38 |
| ▸ | IGF1R | P08069 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789478 | 1.00 | RXRA (0.46) | RXRAPTPN1IGF1RTTRINSR | |
| SCHEMBL5791530 | 0.89 | RXRA (0.59) | RXRAPTPN1GLSGLS2GSK3A | |
| SCHEMBL5791533 | 0.89 | RXRA (0.59) | RXRAPTPN1GLSGLS2GSK3A | |
| SCHEMBL5789480 | 0.87 | RXRA (0.51) | RXRAPTPN1IGF1RGSK3BNPC1 | |
| SCHEMBL5789483 | 0.87 | RXRA (0.51) | RXRAPTPN1IGF1RGSK3BNPC1 | |
| SCHEMBL5790499 | 0.86 | RXRA (0.43) | RXRA | |
| SCHEMBL5492857 | 0.84 | PTPN1 (0.43) | PTPN1IGF1RTTRINSRGSK3B | |
| SCHEMBL14492595 | 0.84 | PTPN1 (0.43) | PTPN1IGF1RTTRINSRGSK3B | |
| SCHEMBL5492859 | 0.84 | PTPN1 (0.43) | PTPN1IGF1RTTRINSRGSK3B | |
| SCHEMBL6449503 | 0.82 | PTPN1 (0.43) | PTPN1IGF1RTTRINSRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | claimed |
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-10-26 | — | — | US | disclosed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1487443-A4 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1487443-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | HDAC5, KAT5, IGFBP5 | RXRA 829/4885PTPN1 2089/4885IGF1R 54/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | RXRA 955/4885PTPN1 1888/4885IGF1R 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.